NHS
Pan Mersey
Area Prescribing Committee

New Medicines Sub Group Review Process for NICE TA reviews



Version: 3.1 (Updated February 2017)
Date Approved: 1 March 2017

New Medicines, Formulary and NICE Subgroup Minutes

Date/Time: Wednesday 12th October 2022
14.00pm – 16.00pm

Item No.	Business Subject	Discussion	Decision Made	Action	Responsibility	Date due
7.	7.1 NPR Icosapent Ethyl (NICE TA805)	AS updated the group regarding this NPR, the PDF version are the documents sent to their APG. The NPR was shared in tandem. This has already been virtually signed off by APG and added to the agenda for information.	We are waiting for confirmation that this has been signed off by ICB and then the formulary can be updated	Action: AS to update the formulary once it has been approved.	AS	November 2022

Executive Prescribing Committee Minutes
Cheshire East and Cheshire West

Date/Time: Thursday 13th October 2022
10.00am – 13.00pm

Item No.	Business Subject	Discussion	Decision Made	Action	Responsibility	Date due
7.7.3	NICE TA805 Icosapent Ethyl	CC updated the committee that NICE TA805 Icosapent Ethyl has been virtually approved by APG with a proposed green formulary position as suitable for prescribing in primary care. To be ratified at the next APG. This is to be included in the collation of NICE TAs for sign off by the ICB executive committee on 20th October 2022.	EPC supported the proposal and will be added to the formulary once this has been approved by ICB executive committee.	AS to add to the formulary once approved		

NHS
Pan Mersey
Area Prescribing Committee

Application and Case for Introduction of New Medicine Service Developments

Application for: _____
(please add drug name & indication)

Purpose of this form: for providers to apply to commissioners for in-year funding of any new drug or extended use of an existing drug (e.g. new indication, new patient group) that will impact on prescribing costs to the commissioner. This includes where the prescribing will be passed on to primary care prescribers or where the drug is prescribed in hospital but generates additional PBR costs or is excluded from the Payment by Results Tariff and drug costs are passed on to commissioners. The annual horizon scanning process should be used as the preferred route to identify the majority of new developments, and any in-year funding applications will be subject to a prioritisation process to establish whether it is a local priority to review within the current financial year. Applicants are advised that prioritisation for review does not guarantee a positive commissioning recommendation outcome.

For minor formulary changes please use the Request for amendment to existing formulary choice or a medicine switch form.

This form is not to be used for Individual Funding Requests (IFR). These are considered where the individual or treatment is exceptional; i.e. where the treatment can be described as exceptional by virtue of the rarity of the condition or the difference of the individual from the generality of similar patients. Separate IFR documentation is available. Sometimes new, innovative treatment options are presented as exceptional: in this case every effort is made to direct the clinical team to the commissioning decision route, via this service development application, although the first few requests via the exceptional treatment route may be considered so as to offer benefit to patients where this is likely.

Process:


Fully completed application form, including organisational sign-off, submitted to Area Prescribing Committee (APC) process
New Medicines Subgroup – assesses application, and undertakes the agreed prioritisation process to establish whether the application is a priority to be reviewed in-year
Priority = NO
Added to following financial year's annual horizon scanning
Priority = YES
APC Subgroup – establishes evidence base and costs of proposed development, consults with stakeholders, discusses with other centres, to form a preliminary recommendation on local commissioning position
Recommendation
Area Prescribing Committee – Formal representation from providers and commissioners. Assesses and discusses subgroup recommendation and stakeholder feedback. Formulates an agreed APC recommendation to commissioners
Recommendation
Commissioners – make formal decision on whether new medicine service development is to be funded within individual commissioning organisations

Please complete this form as fully as possible. Please complete all relevant sections legibly and include full references. Any missing or illegible information will delay the application. You must discuss this application with the relevant Pharmacy Dept. / Medicines Management team within your organisation and obtain organisational support and sign-off for the application before it is submitted. Applications completed by pharmaceutical companies are not acceptable.

Please submit completed form to your organisations representative on the Subgroup in your Pharmacy Dept / Medicines Management Team

Section 1 Clinical information	
Name of medicine (generic and brand name):	
Strength(s) and form(s) of preparation: Dose and schedule of administration:	
Licensed indication(s):	
Proposed Indication (if different from or in addition to the above):	
Is this treatment instead of or in addition to any current treatment? Please give details:	
Reason for proposed change. If replacing current treatment please state how it compares regarding efficacy and safety / tolerability	
Proposed place in therapy relative to other therapies (include protocol for use if available)	

Section 1 Clinical information	
Predicted clinical impact on Primary Care e.g. will it be initiated in hospital only but then prescribed in primary care, or may it be initiated in primary care? Will it require shared care? Please describe:	
Monitoring requirements (e.g. for efficacy, side-effects) – if any? Do these differ from current situation?	
Brief summary of evidence in support of requested medicine / additional use. Meta-analyses, systematic reviews, double-blind randomised controlled trials in peer-reviewed journals. Ensure that evidence to support advantages / benefits of the new medicine over existing treatments is included where appropriate, including criteria for treatment success. Include any relevant morbidity, mortality, health economic and quality of life benefits.	
References Please list and include copies or internet links with the application	

Section 2 Financial information	
Costs: (excluding VAT) Cost per patient per year of medicine: Number of patients per year to be treated for the whole organisation: *Where possible / applicable, include assessment of patient numbers across Pan Mersey area.* Additional costs e.g. day case tariff, tests per patient per year: Any impact on PBR activity? Please give details: Overall financial impact:	
Current treatment(s) usually used (if any): Cost per patient per year currently treated (excluding VAT): Number of patients per year currently treated: Current additional costs e.g. day case tariff, tests per patient per year:	
Predicted financial impact on Primary Care. e.g. Is the medicine hospital only but PBR excluded, will it be initiated in hospital only but then prescribed in primary care, or may it be initiated in primary care? Please describe:	

Section 3 Conflicts of Interest	
Please state any potential conflicts of interest e.g. funding of research, equipment, consulting or speaking fees, other personal or non-personal or family interest etc. in relation to this request:	

Name of Applicant

Role

Organisation name

I confirm I have sent a copy of this form to my organisations Drug & Therapeutics Committee / Medicines Management Committee or equivalent, and it has been approved following the appropriate procedure within my organisation.

Signature of Applicant

Name of Clinical Director / CCG Prescribing Lead

Signature Clinical Director / Prescribing Lead

Name of Chief Pharmacist / Head of Medicines Management

Signature of Chief Pharmacist / Head of Medicines Management

Please note that the application will not be considered unless the Chief Pharmacist / Clinical Director / Prescribing Lead / Head of Medicines Management in your organisation has signed this form.